Venus Remedies has received its first patent for a novel antibiotic combination of carbapenem and amino glycoside from Companies and Intellectual Property Registration Office (CIPRO), South Africa. Pioneering into antibacterial portfolio, Venus has added another international patent to its basket for the antibiotic combination rationally designed to result in a pharmaceutical low dose. Overall, Venus is enjoying a total tally of more than 80 patents for its innovative research products across the globe.
Venus Medicine Research Centre (VMRC) is constantly working on innovating new technologies and drugs for eradicating the most fatal disease in the world. The company has made amazing progress to treat serious fatal mixed multi-bacterial infectious diseases through their novel antibiotic combination of carbapenem and aminoglycoside. Having received this patent grant from CIPRO, South Africa, the company is hopeful of capturing a major share in the market.
Novel antibiotic combination is suitable for the treatment of bacterial/ multi-bacterial infections, and is particularly suitable for catering to the needs of all age groups ranging from the neonates, children, immune compromised patients, and the ones prone to serious fatal mixed multi-bacterial infectious disease.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1462.50 |
Dr. Reddys Lab | 5784.50 |
Cipla | 1451.25 |
Zydus Lifesciences | 1001.15 |
Lupin | 1587.90 |
View more.. |